Advertisement
Advertisement
March 3, 2025
Cook’s Zenith Alpha 2 Thoracic Endovascular Graft Launched in the United States
March 3, 2025—Cook Medical announced that the Zenith Alpha 2 (ZTA2) thoracic endovascular graft is commercially available in the United States. The new ZTA2 device accommodates carbon dioxide (CO2) flushing and has an approved flushing protocol, noted the company.
The company advised that the wide market launch of ZTA2 comes after FDA approval and an early-access prelaunch of the device with select physicians. In January 2025, the first global implantation of the device was performed by Fernando Fleischman, MD; Sukgu Han, MD; and Alyssa Pyun, MD, at Keck Medicine of USC at the University of Southern California in Los Angeles, California.
Cook stated that ZTA2 is the latest iteration of the company’s original Zenith Alpha thoracic device with the same durability and with enhanced features. It is built on Cook’s Zenith graft system and deployment technology.
According to the company, the ZTA2 provides the option to flush the device with either saline alone or saline and CO2. The press release noted that flushing with CO2, which is denser than air, helps to displace any remaining air within the device and minimize air emboli.1
1. Company-held nonclinical testing.
Advertisement
Advertisement
